Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Avangina A"'
Autor:
Maria Susana Mallea-Gil, Ignacio Bernabeu, Adriana Spiraquis, Alejandra Avangina, Lourdes Loidi, Carolina Ballarino
Publikováno v:
Case Reports in Endocrinology, Vol 2016 (2016)
Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary m
Externí odkaz:
https://doaj.org/article/0077c11b4c2f47179bbf11ad7ee7a456
Autor:
Carolina Ballarino, Lourdes Loidi, Ignacio Bernabeu, Adriana Spiraquis, Alejandra Avangina, María Susana Mallea-Gil
Publikováno v:
Case Reports in Endocrinology. 2016:1-5
Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d65630d8ce603650344035d841b53009
https://doi.org/10.1155/2016/2087102
https://doi.org/10.1155/2016/2087102
Autor:
Mallea-Gil, Maria Susana, Bernabeu, Ignacio, Spiraquis, Adriana, Avangina, Alejandra, Loidi, Lourdes, Ballarino, Carolina
Publikováno v:
Case Reports in Endocrinology.
Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=hindawi_publ::1e72e4f73c54222b9c52958bdf9bf964
Autor:
Mallea-Gil, Maria Susana, Bernabeu, Ignacio, Spiraquis, Adriana, Avangina, Alejandra, Loidi, Lourdes, Ballarino, Carolina
Publikováno v:
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname
instname
Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::25324f913b83234404c43082e7531a97
https://hdl.handle.net/10347/16081
https://hdl.handle.net/10347/16081
Autor:
Susana Mallea-Gil, Maria, Bernabeu, Ignacio, Spiraquis, Adriana, Avangina, Alejandra, Loidi, Lourdes, Ballarino, Carolina
Publikováno v:
Case Reports in Endocrinology; 2016, Vol. 2016 Issue: 1